BofA analyst David Li upgraded BeiGene (ONC) to Buy from Neutral with a price target of $320, up from $207. The firm raised its revenue forecast for Brukinsa in light of its sharp sales growth in the U.S. and lifts Beigene’s overall revenue forecasts for 2025, 2026 and 2027 by 6.0%, 11.8% and 15.5%, respectively. The firm also adds BGB-43395 and BGN-16673 to its model as these assets approach late-stage clinical trials, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene’s Strong Market Position and Growth Potential Driven by Zanubrutinib Sales and Promising Financial Outlook
- BeiGene’s Strong Financial Performance and Promising Outlook Earns Buy Rating from Analyst
- BeiGene granted orphan designation for sonrotoclax
- BeiGene price target raised to $313 from $259 at Macquarie
- BeiGene price target raised to $348 from $345 at Guggenheim